NASDAQ:QDEL • US2197981051
The current stock price of QDEL is 19.86 USD. Today QDEL is down by -4.66%. In the past month the price decreased by -31.75%. In the past year, price decreased by -45.02%.
ChartMill assigns a technical rating of 0 / 10 to QDEL. When comparing the yearly performance of all stocks, QDEL is a bad performer in the overall market: 92.03% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to QDEL. Both the profitability and financial health of QDEL have multiple concerns.
On February 11, 2026 QDEL reported an EPS of 0.46 and a revenue of 723.60M. The company beat EPS expectations (6.57% surprise) and beat revenue expectations (0.14% surprise).
14 analysts have analysed QDEL and the average price target is 35.87 USD. This implies a price increase of 80.61% is expected in the next year compared to the current price of 19.86.
For the next year, analysts expect an EPS growth of 4.37% and a revenue growth 2.46% for QDEL
Over the last trailing twelve months QDEL reported a non-GAAP Earnings per Share(EPS) of 2.12. The EPS increased by 14.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.62% | ||
| ROE | -58.93% | ||
| Debt/Equity | 1.29 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.61 | 195.75B | ||
| ISRG | INTUITIVE SURGICAL INC | 48.29 | 175.278B | ||
| SYK | STRYKER CORP | 24.19 | 140.034B | ||
| BSX | BOSTON SCIENTIFIC CORP | 20.56 | 106.692B | ||
| EW | EDWARDS LIFESCIENCES CORP | 28.34 | 48.896B | ||
| IDXX | IDEXX LABORATORIES INC | 41.18 | 48.604B | ||
| BDX | BECTON DICKINSON AND CO | 12.14 | 47.113B | ||
| RMD | RESMED INC | 20.6 | 36.847B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 14.63 | 34.468B | ||
| DXCM | DEXCOM INC | 27.04 | 26.455B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11 | 18.25B | ||
| PODD | INSULET CORP | 37.18 | 16.923B | ||
| HOLX | HOLOGIC INC | 15.4 | 16.875B |
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
QuidelOrtho Corp. operates as a vitro diagnostics company. The company is headquartered in San Diego, California and currently employs 6,500 full-time employees. The firm specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. The company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
IPO: 1991-02-01
QUIDELORTHO CORP
9975 Summers Ridge Road
San Diego CALIFORNIA 92121 US
CEO: Douglas C. Bryant
Employees: 6600
Phone: 18887057274
QuidelOrtho Corp. operates as a vitro diagnostics company. The company is headquartered in San Diego, California and currently employs 6,500 full-time employees. The firm specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. The company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
The current stock price of QDEL is 19.86 USD. The price decreased by -4.66% in the last trading session.
QDEL does not pay a dividend.
QDEL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on QDEL.
QUIDELORTHO CORP (QDEL) has a market capitalization of 1.35B USD. This makes QDEL a Small Cap stock.
QUIDELORTHO CORP (QDEL) will report earnings on 2026-05-05.